Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs
16 nov. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end...